arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

NEOGENOMICS INC

NEO
$16.57 ▲ +1.01 (+6.49%) at close
Industrials ·Services-Testing Laboratories ·USServices-Testing Laboratories
64 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

NEOGENOMICS INC faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.1B
Dividend Yield
Revenue Growth 11.1%
Op. Margin -9.8%
ROIC -2.1%
FCF / Share $-0.10
Trailing P/E
Price / Book 2.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

64-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$186.67M
↑ +11.1%
Net Income Profit after all expenses
$-17.11M
↑ +34.0%
Operating Margin Operating profit as % of sales
-9.8%
↑ +32.1% 12th
FCF / Share Free cash flow per share
$-0.10
↑ +56.6%
Long-Term Debt Long-term obligations
$341.86M
↓ -36.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
15
Returns
32
Financial Health
36
Cash Quality
29

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 64 quarters